IPIX (Innovation Pharmaceuticals) Current Accrued Expense: $1.62 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals Current Accrued Expense?

Innovation Pharmaceuticals IPIX Current Accrued Expense is $1.62 Mil as of Sep. 2023.

Innovation Pharmaceuticals's Current Accrued Expense for the quarter that ended in Sep. 2023 was $1.62 Mil.

Innovation Pharmaceuticals's quarterly Current Accrued Expense increased from Mar. 2023 ($1.60 Mil) to Jun. 2023 ($1.62 Mil) and increased from Jun. 2023 ($1.62 Mil) to Sep. 2023 ($1.62 Mil).

Innovation Pharmaceuticals's annual Current Accrued Expense declined from Jun. 2021 ($2.13 Mil) to Jun. 2022 ($1.58 Mil) but then increased from Jun. 2022 ($1.58 Mil) to Jun. 2023 ($1.62 Mil).

Innovation Pharmaceuticals Current Accrued Expense Related Terms

Innovation Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Current Accrued Expense Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.08 3.08 2.13 1.58 1.62

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.58 1.60 1.62 1.62

Innovation Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.62 Mil mean?
Innovation Pharmaceuticals (IPIX) has a Current Accrued Expense of $1.62 Mil as of Sep. 2023. Current Accrued Expense records the total amount of accrued expenses. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Current Accrued Expense too high?
Innovation Pharmaceuticals' current Current Accrued Expense is $1.62 Mil.
How does Innovation Pharmaceuticals' Current Accrued Expense compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Current Accrued Expense of $1.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Current Accrued Expense is $1.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Current Accrued Expense of $1.62 Mil. The current Current Accrued Expense is $1.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Current Accrued Expense is $1.62 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.